Literature DB >> 21988234

Colistin pharmacokinetics: the fog is lifting.

W Couet1, N Grégoire, S Marchand, O Mimoz.   

Abstract

Colistin is a re-emerging old antibiotic that is used to treat multidrug-resistant infections in critically ill patients. It corresponds to a mixture of at least 30 different compounds administered as inactive derivatives. Therefore, colistin pharmacokinetics are quite difficult to investigate and complex to predict. However specific chromatographic methods have been made available in recent years, leading to a series of modern pharmacokinetic studies after intravenous administration of the prodrug to critical-care patients; these have been conducted by a few groups and have only been recently published. The objective of this article was to conduct a critical review of these very informative modern pharmacokinetic studies and to provide prospective thoughts.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21988234     DOI: 10.1111/j.1469-0691.2011.03667.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  33 in total

1.  Colistin distribution in the peritoneal fluid of a patient with severe peritonitis.

Authors:  Olivier Mimoz; Franck Petitpas; Nicolas Grégoire; Patrice Gobin; Sandrine Marchand; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

2.  Preliminary method for direct quantification of colistin methanesulfonate by attenuated total reflectance Fourier transform infrared spectroscopy.

Authors:  Krista L Niece; Kevin S Akers
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

3.  Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.

Authors:  Timothy P Gauthier; William R Wolowich; Arathi Reddy; Ennie Cano; Lilian Abbo; Laura B Smith
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.

Authors:  Tiffany A Thomas; Emily C Broun; Kirsten M Abildskov; Christine J Kubin; Jennifer Horan; Michael T Yin; Serge Cremers
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

Review 5.  Colistin and polymyxin B: peas in a pod, or chalk and cheese?

Authors:  Roger L Nation; Tony Velkov; Jian Li
Journal:  Clin Infect Dis       Date:  2014-04-03       Impact factor: 9.079

6.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin.

Authors:  Aline Vidal Lacerda Gontijo; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

7.  New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.

Authors:  N Grégoire; O Mimoz; B Mégarbane; E Comets; D Chatelier; S Lasocki; R Gauzit; D Balayn; P Gobin; S Marchand; W Couet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 8.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803

9.  Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.

Authors:  Marie Abdallah; Olawole Olafisoye; Christopher Cortes; Carl Urban; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

Review 10.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.